Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université de Montréal

$27,000.00

Aspirin in Subclinical Coronary Artery Disease : A Pilot Randomised Controlled Trial (ASCAD-P Trial)

EF 2025-26

Résumé
Cardiovascular disease is the leading cause of mortality worldwide and a substantial contributor to excess health care costs. Globally, 437 million disability-free life-years were lost in 2023 to cardiovascular disease, a 40% increase since 1990. In Canada, cardiovascular disease annually represents a $13.1 billion burden to the economy and claims over 120,000 lives—this fuels prevention and early detection efforts to improve cardiovascular health. Subclinical coronary artery disease is an area of rising interest where health professionals identify asymptomatic narrowing of heart vessels at an early stage. Despite appearing healthy, these patients have an increased risk of heart attack. Low-dose aspirin is a safe, readily available, and inexpensive drug that has been proven effective to reduce mortality in patients with prior heart attacks. However, its role in subclinical coronary artery disease and primary prevention remains unclear. Further research is required to clarify whether benefits outweigh risks. The ASCAD-P trial is a first step towards answering this question. It aims to assess the feasibility of a protocol studying the role of aspirin for cardiovascular prevention in patients with subclinical coronary artery disease. Throughout the 2-year study period, investigators will recruit and follow participants, identify logistical barriers, monitor safety, and assess patient acceptability. This pilot study will take place at the Montreal Heart Institute, a world-renowned center of cardiovascular expertise. If successful, it will provide stepping stones to a full-scale multi-center trial, which would generate robust and reliable data to clarify the role of low-dose aspirin in subclinical coronary artery disease.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572726
Name
Gagnon Cyril
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Aspirin in Subclinical Coronary Artery Disease : A Pilot Randomised Controlled Trial (ASCAD-P Trial)
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Aspirin; Atherosclerosis; Cardiovascular Health; Coronary Artery Disease; Major Adverse Cardiovascular Events (Mace); Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Sex- And Gender-Based Analysis; Subclinical Diseases
Abstract
Cardiovascular disease is the leading cause of mortality worldwide and a substantial contributor to excess health care costs. Globally, 437 million disability-free life-years were lost in 2023 to cardiovascular disease, a 40% increase since 1990. In Canada, cardiovascular disease annually represents a $13.1 billion burden to the economy and claims over 120,000 lives—this fuels prevention and early detection efforts to improve cardiovascular health. Subclinical coronary artery disease is an area of rising interest where health professionals identify asymptomatic narrowing of heart vessels at an early stage. Despite appearing healthy, these patients have an increased risk of heart attack. Low-dose aspirin is a safe, readily available, and inexpensive drug that has been proven effective to reduce mortality in patients with prior heart attacks. However, its role in subclinical coronary artery disease and primary prevention remains unclear. Further research is required to clarify whether benefits outweigh risks. The ASCAD-P trial is a first step towards answering this question. It aims to assess the feasibility of a protocol studying the role of aspirin for cardiovascular prevention in patients with subclinical coronary artery disease. Throughout the 2-year study period, investigators will recruit and follow participants, identify logistical barriers, monitor safety, and assess patient acceptability. This pilot study will take place at the Montreal Heart Institute, a world-renowned center of cardiovascular expertise. If successful, it will provide stepping stones to a full-scale multi-center trial, which would generate robust and reliable data to clarify the role of low-dose aspirin in subclinical coronary artery disease.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gagnon, Cyril
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~